A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease

The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).

开始日期2017-10-12

申办/合作机构

Kadmon Holdings, Inc.

NCT03096080

/ Completed临床1期

A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

This study evaluates safety and tolerability of a single ascending dose of a tesevatinib liquid formulation administered to pediatric subjects with ARPKD.

开始日期2017-08-24

申办/合作机构

Kadmon Corp. LLC

NCT02844439

/ Completed临床2期

A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

开始日期2016-06-01

申办/合作机构

Kadmon Corp. LLC

100 项与泰西伐替尼相关的临床结果

登录后查看更多信息

100 项与泰西伐替尼相关的转化医学

登录后查看更多信息

100 项与泰西伐替尼相关的专利（医药）

登录后查看更多信息

项与泰西伐替尼相关的文献（医药）

2024-02-01·JOURNAL OF MATHEMATICAL CHEMISTRY

Identification of potential oral cancer drugs as Bcl-2 inhibitors from known anti-neoplastic agents through docking studies

作者: Chandan Raychaudhury ; Debnath Pal ; Shreyaa Srinivasan

Oral Cancer is one of the major killers in India and of global concern.An attempt has been made here to identify small mol. inhibitors of Bcl-2 (B-cell lymphoma 2) protein through docking studies in search of new oral cancer drugs from a curated set of 276 known anti-neoplastic agents obtained from PubChem.The Bcl-2 protein (PDB id:6QGH), being complexed with ligand ABT-263, has been detached from the complex.The ligand-free protein and 276 compounds have been prepared for docking studies using corresponding tools available in Discovery Studio (DS), ver.4.1.The 276 compounds have been docked on the first site of the protein using LibDock docking program available in DS.By considering Methotrexate as the reference compound (LibDock score: 114.76), we have identified 25 compounds as the most potential oral cancer drugs having LibDock scores greater than 100.Another set of 114 compounds with LibDock scores between 80 and 100 have also been identified as the next set of potential drug candidates and some of them show anti-apoptosis properties.Two other compounds with LibDock scores below 80 have been identified for comparative analyses with some high-scoring compoundsThe docking results have been given in tables and pictures (screenshots) of the docked poses of selected compounds have been shown to illustrate the findings.Finally, the most suitable potential compounds have been identified by applying Lipinski′s Rule of 5.The present approach using known anti-neoplastic agents is believed to help discover potential anti-oral cancer drug candidates.

2022-08-01·Gene

Comprehensive analysis of placental gene-expression profiles and identification of EGFR-mediated autophagy and ferroptosis suppression in intrahepatic cholestasis of pregnancy

Article

作者: Fang, Yan ; Fang, Dajun

Intrahepatic cholestasis of pregnancy (ICP) was the most common liver disease specific to pregnancy. The symptoms of ICP were maternal pruritus and increased bile acid level in serum which was related to preterm birth, fetal distress, meconium-stained amniotic fluid and stillbirth. However, the mechanism of ICP progression on fetal development remained obscure. Sequencing data of 2 normal placenta samples and 4 intrahepatic cholestasis samples during pregnancy was analyzed by GEO2R. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used for analysis of differentially expressed genes. MCODE - A plug-in of Cytoscape was used for molecular complex detection. STRING, Cytoscape, GeneMANIA, NetworkAnalyst, TransmiR, JASPAR, DGIdb and DrugBank were used in this study. Furthermore, histopathological and cell experiments were used to verify our results. Our study identified the key KEGG pathway and four MCODEs which were closely with ICP development, further, sorted by degree centrality, we showed top 30 genes from 7209 differential genes, such as TP53, SRC, EGFR, ESR1, IL10, CD8A, MAPK3, PTPRC, EGF, KIT, ITGAM, LEP and CSF2, etc. Moreover, these hub genes participated in JAK-STAT3 signaling pathway and STAT1/3 regulated these genes expression in a direct way or miRNA-mediated manner. Drug-target analysis about up-regulated genes among hub genes showed that these genes contained multiple drug action site. Furthermore, hub gene-EGFR was associated with destroyed autophagy and ferroptosis. In conclusion, our study analyzed key genes and pathways in ICP development. JAK-STAT3 pathway and EGFR might be a potential target for ICP therapy.

2022-07-23·Disease markers

Gene Identification and Potential Drug Therapy for Drug-Resistant Melanoma with Bioinformatics and Deep Learning Technology

Article

作者: Liu, Muge ; Xu, Yingbin

Background. Melanomas are skin malignant tumors that arise from melanocytes which are primarily treated with surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, etc. Targeted therapy is a promising approach to treating advanced melanomas, but resistance always occurs. This study is aimed at identifying the potential target genes and candidate drugs for drug-resistant melanoma effectively with computational methods. Methods. Identification of genes associated with drug-resistant melanomas was conducted using the text mining tool pubmed2ensembl. Further gene screening was carried out by GO and KEGG pathway enrichment analyses. The PPI network was constructed using STRING database and Cytoscape. GEPIA was used to perform the survival analysis and conduct the Kaplan-Meier curve. Drugs targeted at these genes were selected in Pharmaprojects. The binding affinity scores of drug-target interactions were predicted by DeepPurpose. Results. A total of 433 genes were found associated with drug-resistant melanomas by text mining. The most statistically differential functional enriched pathways of GO and KEGG analyses contained 348 genes, and 27 hub genes were further screened out by MCODE in Cytoscape. Six genes were identified with statistical differences after survival analysis and literature review. 16 candidate drugs targeted at hub genes were found by Pharmaprojects under our restrictions. Finally, 11 ERBB2-targeted drugs with top affinity scores were predicted by DeepPurpose, including 10 ERBB2 kinase inhibitors and 1 antibody-drug conjugate. Conclusion. Text mining and bioinformatics are valuable methods for gene identification in drug discovery. DeepPurpose is an efficient and operative deep learning tool for predicting the DTI and selecting the candidate drugs.

项与泰西伐替尼相关的新闻（医药）

2026-04-30

·大毒师

2026年4月全球多囊肾ADPKD 治疗研发管线-进入临床阶段的统计

以下项目共同展现了 ADPKD 治疗领域从单一通路激素控制向多元化、机制驱动型疗法的明显转变，其中 HRS 9057 代表了新兴的细胞内小分子药物类别，RNA 疗法着眼于基因调控，而生物制剂和蛋白质矫正剂则拓展了精准治疗的范围。 ADPKD囊肿发病机制及相关治疗。图示为ADPKD发病机制中涉及的主要分子和细胞机制，包括：PC1/PC2功能丧失和钙稳态紊乱；影响纤毛形成的鞭毛内转运（IFT）复合物突变；JAK/STAT、NF-κB、Wnt/β-catenin和mTOR信号通路改变；Ras/MAPK和PI3K/Akt异常激活；cAMP信号通路失调；PC1错误折叠导致的内质网应激；以及线粒体功能障碍伴糖酵解和乳酸生成改变。图示的药物干预措施包括托伐普坦（V2受体阻滞剂）、二甲双胍（AMPK激活剂）、雷帕霉素/依维莫司（mTOR抑制剂）以及PDE和钙调磷酸酶通路调节剂。图中底部展示了新兴的基因疗法（CRISPR/Cas9、AAV介导的递送、反义寡核苷酸）。实线红线表示活跃的信号通路，虚线红线表示被破坏或抑制的通路。[Kolísková P (2024) Primary cilia-associated signalling in squamous cell carcinoma of head and neck region. Front. Oncol. 14:1413255. doi: 10.3389/fonc.2024.1413255] 全球 ADPKD 治疗方案开发机制集群图 🌍JMKX003142（济民可信，中国） JMKX003142 是一种首创的小分子抑制剂，靶向细胞内囊肿增殖通路。临床前研究表明，该化合物能剂量依赖性地抑制肾上皮细胞增殖，且无钩状毒性。目前，该化合物正在中国开展一项针对快速进展型常染色体显性多囊肾病 (ADPKD) 患者的 II 期随机、双盲、安慰剂对照临床试验，同时正在进行 I 期 QTc 间期安全性研究。 🌍HRS 9057（成都盛迪药业/江苏恒瑞，中国） HRS 9057是由江苏恒瑞旗下子公司成都盛迪药业研发的一种中国原创的I类创新小分子药物。该药旨在作为一种疾病修饰疗法用于治疗常染色体显性多囊肾病（ADPKD），其作用机制为在细胞内抑制肾上皮细胞增殖和囊肿形成。与血管加压素拮抗剂不同，HRS 9057并非主要通过激素通路发挥作用，而是靶向驱动囊肿形成的细胞内在信号网络。该化合物于2023年底获得国家药品监督管理局（NMPA）批准，进入ADPKD的临床试验，目前在中国处于早期I/II期临床开发阶段，主要研究重点是安全性、耐受性和探索性疗效。 🌍Tamibarotene (RN 014) –日本Rege Nephro 公司塔米巴罗汀由日本 Rege Nephro 公司研发，是一种基于诱导多能干细胞 (iPSC) 衍生疾病模型而开发的视黄酸受体 (RAR) 激动剂，用于治疗常染色体显性多囊肾病 (ADPKD)。其作用机制在于调节抑制囊肿形成和上皮细胞去分化的转录程序。该药物为口服给药，是一种非激素、非 cAMP 直接作用的治疗方法。塔米巴罗汀已在日本完成 II 期临床试验的受试者招募，该试验设有安慰剂对照，是目前处于临床开发阶段的、由日本主导的最先进的 ADPKD 创新项目之一。 🌍Farabursen (RGLS8429) – Regulus / 诺华 Farabursen 是一种靶向 miR-17 的反义寡核苷酸，最初由 Regulus Therapeutics 开发，后被诺华收购并继续推进研发。该药物旨在通过解除 miR-17 介导的抑制作用来恢复 PKD1 和 PKD2 的表达，从而从遗传信号核心治疗常染色体显性多囊肾病 (ADPKD)。Farabursen 在 1b 期临床研究中展现出令人鼓舞的生物标志物和肾脏体积改善效果，目前正在包括美国以外地区在内的多个国家开展III 期临床开发。它是目前最成熟的基于 RNA 的 ADPKD 疗法之一。 🌍VX 407 – Vertex Pharmaceuticals VX 407 是一种蛋白质校正小分子，旨在改善特定 PKD1 突变亚群中缺陷多囊蛋白 1 (PC1) 的折叠和转运。由Vertex公司开发的VX 407项目采用精准医疗策略，针对那些基因突变导致PC1蛋白错误折叠但可能可恢复的患者。VX 407目前正在全球范围内开展II期临床试验，具有高度的突变选择性，这意味着它未来将主要用于基因分层的ADPKD患者群体，而非普遍使用。 🌍艾伯维/卡利科抗妊娠相关血浆蛋白A抗体（ABBV CLS 628） ABBV CLS 628 是一种靶向妊娠相关血浆蛋白A（PAPP A）的单克隆抗体，由艾伯维和卡利科生命科学公司联合开发。PAPP A 调节胰岛素样生长因子信号通路，从而促进囊肿扩张。该生物制剂代表了一种非小分子药物治疗常染色体显性多囊肾病（ADPKD）的方法，目前正在国际临床试验中心进行II期临床开发。它反映了人们对肾小管特异性机制之外的生长因子调节机制日益增长的兴趣。 🌍SGLT2抑制剂（达格列净、恩格列净——学术界和产业界项目） SGLT2抑制剂（如达格列净和恩格列净）最初获批用于治疗糖尿病和慢性肾病（CKD），目前主要在欧洲和日本进行ADPKD的临床试验。它们的作用机制是间接的，涉及代谢、血液动力学和抗炎作用，而非直接抑制囊肿。目前正在进行多项 II 期和 III 期学术试验，通常设有安慰剂或标准治疗对照组，其中包括将 SGLT2 抑制剂与托伐普坦联合使用的研究。 🌍利昔伐坦 (Lixivaptan) – Centessa Pharmaceuticals 利昔伐坦是一种新一代血管加压素 V2 受体拮抗剂，旨在保留托伐普坦的促囊肿作用，同时降低肝毒性风险。目前，利昔伐坦正处于全球（包括美国以外地区）III 期临床试验的后期阶段，其作用机制并非改变，而是一种优化。 [Clerici S, Boletta A. Polycystic kidney disease Trends in Molecular Medicine, 2026; 32, 313-314] 🌍全球 ADPKD 治疗研发管线药物公司地区阶段核心机制新颖性×成熟度关键状态说明主要网址链接托伐普坦（OPC 41061）大冢制药美国、欧盟和日本批准V2受体拮抗剂6/10目前唯一获批的疾病修饰疗法（DMT），但其疗效受限于利尿和肝毒性https://pkdcure.org/research/pipeline利昔伐坦 Centessa 美国和欧盟 III 期新一代 V2 受体拮抗剂（对肝脏更安全） 7/10 正处于已验证通路的后期优化阶段 https://www.abnewswire.com/pressreleases/autosomal-dominant-polycystic-kidney-disease-pipeline-drugs-report-2025-innovative-treatments-drug-candidates-clinical-trials-and-market-trends_767131.htmlABBV‑CLS‑628AbbVie / Calico美国和欧盟II 期抗 PAPP A 单克隆抗体8/10FDA 快速通道；生长因子生物学https://clinicaltrials.gov/study/NCT06902558Farabursen (RGLS8429) Regulus → Novartis 美国和欧盟 II 期 anti‑miR‑17 (RNA therapy) 9/10 恢复PKD1/2表达；强有力的生物标志物数据 https://pkdcure.org/research/pipeline/VX‑407 (AGLOW)Vertex美国和欧盟II 期PC1蛋白校正剂8/10针对PKD1变异体的精准治疗https://clinicalstudies.pkdcure.org/clinical-studies/HRS-9057 恒瑞/盛迪中国 I/II期细胞内囊肿生长途径抑制剂 7/10 首创非激素小分子 https://bydrug.pharmcube.com/news/detail/bff0f912050a13fecce02c651728024e他米巴罗汀 (RN 014)Rege Nephro日本II期视黄酸受体 (RAR) 激动剂7/10诱导多能干细胞发现；转录调控https://clinicaltrials.gov/study/NCT06289998恩格列净（ADPKD）汉诺威医学院欧盟、美国 III 期 SGLT2 抑制剂（代谢） 6/10 慢性肾病药物再利用 https://clinicaltrials.eu/trial/study-of-empagliflozin-for-patients-with-autosomal-dominant-polycystic-kidney-disease/达格列净——STOP PKD科隆大学欧盟II 期SGLT2 抑制剂5/10学术性概念验证http://pkdinternational.org/studiesDAPA Tolvaptan 组合庆应大学日本 II 期 SGLT2 + V2RA 6 / 10 组合策略 https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000046275兰瑞肽（DIPAK）欧盟学术研究欧盟III期生长抑素类似物5/10肾脏获益有限https://www.ajkd.org/article/S0272-6386%2824%2901032-1/fulltext奥曲肽LAR 学术欧盟 II/III期生长抑素类似物 5/10 长效靶向抑制剂二甲双胍美国国立卫生研究院资助的学术研究美国、欧盟II期AMPK激活4/10代谢再利用方法https://pmc.ncbi.nlm.nih.gov/articles/PMC6010317/依维莫司（Everolimus）诺华欧盟 II期 mTOR抑制剂 3/10 长期疗效不佳博舒替尼（Bosutinib）辉瑞美国、欧盟II期Src激酶抑制剂3/10毒性限制替塞伐替尼（Tesevatinib，KD019） Kadmon 美国、欧盟 II期 Src/EGFR抑制剂 3/10 已停止研发雷公藤内酯醇学术中国II 期抗增殖药物4/10区域特异性https://pmc.ncbi.nlm.nih.gov/articles/PMC5123007/AZD1613（PIONEER PKD）阿斯利康美国、欧盟 I 期新型小分子 4/10 早期安全性/药代动力学 https://clinicalstudies.pkdcure.org/clinical-studies/GLP-1 RA美国学术界美国II 期代谢/抗炎4/10探索性用途再利用RGLS4326 Regulus 美国 I 期第一代抗 miRNA 药物 4 / 10 Farabursen 的前体 https://pkdcure.org/research/pipeline/JMKX003142济民可信中国II 期细胞内囊肿增殖通路抑制剂7/10中国研发的 BIC 潜力；非激素类小分子

2016-07-26

·BioSpace

Why Investors are Still Throwing Cash at Debt-Ridden Kadmon, a NYC Biotech Founded By Ex-Con Sam Waksal

July 26, 2016 By Mark Terry , BioSpace.com Breaking News Staff Kadmon Corporation , based in New York, registered in June with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) to raise $115 million. Now that the IPO is about to launch, investors have to balance the potential science of the company with its questionable finances and the colorful and crooked history of its founders. Despite its science, Kadmon is better known for its founder, Sam Waksal . Waksal is best known not for his former company, ImClone , but for the insider trading scandal that put both him and Martha Stewart in prison. And one of the peculiarities of the IPO is that Sam Waksal, because of his five-year prison sentence, had to resign from the company because he has a lifelong ban from serving as an officer in a public company. The company is currently being run by Sam’s brother Harlan Waksal, who is president and chief executive officer. Sam Waksal received $3 million in severance, and is eligible for up to $6.75 million in milestone payments, and up to $15 million as part of various development deals. But with the IPO scheduled for this week, a number of analysts seem to be incredulous, at best. In an article in STAT, a number of unidentified biotech investors expressed their dismay. “It doesn’t make much sense to me,” one told STAT. “Are there really enough suckers out there?” In 2001, Sam Waksal received news from the U.S. Food and Drug Administration (FDA) that ImClone’s application for cancer drug Erbitux, was being rejected. He then attempted to unload company stock and told various family members and friends that they should, too. Martha Stewart sold off shares of her ImClone stock based on illegally obtained information from her broker. She served five months in federal prison and some time on house arrest. Waksal, sentenced in 2003, got out of prison in 2009. Eli Lilly and Company acquired ImClone in 2008 for $6.5 billion. Erbitux was approved by the FDA in 2004 and went on eventually to be a blockbuster drug. Kadmon has three products in its pipeline, KD025, which is being investigated in a number of disorders, including psoriasis, idiopathic pulmonary fibrosis, chronic graft-versus-host disease, and arthritis; tesevatinib, being studied for oncology indications and polycystic kidney disease; and KD034 in Wilson’s Disease. STAT writes, “Kadmon’s commercial business is a fraying operation that relies almost entirely on sales of ribavirin, an aging treatment for hepatitis C. The drug is rapidly becoming obsolete as far more effective therapies come on the market. Kadmon’s sales plummeted from $63.5 million in 2014 to $29.3 million last year, and, in documents filed with the SEC, Kadmon acknowledges that its current drugs will ‘contribute insignificantly to revenue in 2017 and beyond.’” A lot depends on the success of the IPO. The company has a very high debt level and its cash burn rate could push it into bankruptcy by the end of the year. Maxim Jacobs , director of healthcare research at investment group, Edison, told STAT, “They’re burning cash like it’s 1999 here.” The strategy, apparently, is to prop up lackluster commercial part of the company’s operations until its pipeline can get approved. But the $100 million+ it’s trying to raise will only last through next year. Its top drug candidates are only in Phase I or II trials, years from possible approval. Although Sam Waksal has proven adept in finding promising drugs—at least once, anyway—investors should probably be leery over his criminal record and tendency to exaggerate, what STAT refers to as “hyperbolic cheerleading.” Kadmon and Sam Waksal are also being sued by several people, including Anastasios “Tommy” Belesis , former head of John Thomas Financial , who has been permanently barred from trading securities. Another lawsuit awaiting trial indicates that Waksal made a deal with investors for a 6 percent stake in the company, then did not fulfill his part of it after they held up their end. Although Kadmon and Waksal make for a colorful story, in terms of investors and this IPO, it clearly seems: Let the buyer beware.

IPO上市批准并购临床1期

100 项与泰西伐替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11772	泰西伐替尼	-	DB11973

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌IIIB期	临床3期	美国	Kadmon Corp. LLC	2011-12-14
复发性胶质母细胞瘤	临床2期	美国	Kadmon Corp. LLC	2016-06-01
常染色体显性多囊肾病	临床2期	美国	Kadmon Corp. LLC	2015-12-25
脑转移瘤	临床2期	美国	Kadmon Corp. LLC	2015-11-01
软脑膜转移性恶性肿瘤	临床2期	美国	Kadmon Corp. LLC	2015-11-01
HER2阳性转移性乳腺癌	临床2期	美国	Kadmon Corp. LLC	2014-05-01
常染色体隐性遗传性多囊肾	临床1期	美国	Kadmon Corp. LLC	2017-08-24
转移性乳腺癌	临床1期	美国	Exelixis, Inc.	2008-06-01
晚期恶性实体瘤	临床1期	美国	Kadmon Corp. LLC	2006-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03203642 (CTgov)	临床2期	常染色体显性多囊肾病	80	Tesevatinib (Tesevatinib)	積鹽夢窪鬱選衊觸構鬱(構製淵齋選糧觸鹽鏇窪) = 廠積餘餘繭淵遞遞糧衊醖網壓膚範鹹網顧範糧 (繭積窪淵製選觸範廠窪, 0.0059) 更多	-	2023-02-06
				Placebo (Placebo)	積鹽夢窪鬱選衊觸構鬱(構製淵齋選糧觸鹽鏇窪) = 窪繭艱糧鬱鹽壓製糧獵醖網壓膚範鹹網顧範糧 (繭積窪淵製選觸範廠窪, 0.0057) 更多
NCT01559363 (CTgov)	临床1/2期	常染色体显性多囊肾病	69	Tesevatinib (Phase 1b: Cohort 1: Tesevatinib 50 mg Once Daily Dosing)	廠遞糧醖製窪網觸襯廠 = 製選餘網鬱構積艱淵糧築窪窪顧選醖積壓鏇餘 (蓋衊網鏇獵餘構遞簾遞, 觸餘糧餘選獵製齋簾網 ~ 築積餘鹽鹽齋簾夢淵窪) 更多	-	2022-11-08
				Tesevatinib (Phase 1b: Cohort 2: Tesevatinib 100 mg Once Daily Dosing)	廠遞糧醖製窪網觸襯廠 = 築壓鹹餘醖鹽繭繭膚憲築窪窪顧選醖積壓鏇餘 (蓋衊網鏇獵餘構遞簾遞, 齋夢憲膚蓋齋膚憲築願 ~ 鏇鏇艱膚獵壓醖鹹蓋選) 更多
SILK (ASN2019)	临床1/2期	常染色体显性多囊肾病	13	Tesevatinib 50 mg QD	鏇觸窪積淵鏇蓋構糧觸(糧淵築夢選鹹憲襯積製) = Grade 3 AEs were reported in 3 patients (CHF, HTN, and Herpes zoster) and were considered unlikely or unrelated to study drug 遞選積蓋遞積築製廠餘 (網範襯廠醖醖廠築醖繭 ) 更多	积极	2019-11-05
NCT02154529 (ASCO2016)	临床1/2期	HER2阳性转移性乳腺癌	8	Tesevatinib 300 mg QD	壓膚蓋壓繭獵鏇蓋簾製(廠構製憲糧窪齋顧範憲) = Grade 3 diarrhea and Grade 3 QTc prolongation 簾範築繭構鹹襯繭襯壓 (蓋餘簾糧壓夢鑰簾糧築 )	-	2016-05-20
				Tesevatinib 350 mg QD
ASN2015	N/A	常染色体显性多囊肾病	46	Tesevatinib 150 mg/day	艱觸鹽築繭餘鑰窪夢憲(膚餘艱夢築襯鏇鬱網簾) = In oncology trials the most common adverse events (AEs) were EGFR inhibitor AEs of acneiform rash and diarrhea. 壓觸糧鹽醖簾蓋鏇獵糧 (襯網繭艱憲襯製壓遞網 ) 更多	不佳	2015-11-03
				Tesevatinib 100 mg/day
ASCO2008	临床2期	非小细胞肺癌	41	XL647 350 mg (intermittent cohort)	鬱網遞製獵網齋觸淵積(獵鹹齋簾艱觸糧鑰廠蓋) = 夢窪願構廠簾範鬱衊遞醖鑰廠醖壓鹽積繭衊築 (製鑰遞觸鑰淵鏇網夢網 ) 更多	-	2008-05-20
ASCO2008	临床1期	晚期恶性实体瘤	31	XL647	憲網構糧網醖遞憲襯憲(夢鬱窪選憲鏇遞憲繭餘) = 窪糧構淵觸醖範製顧築積鑰鹹襯鏇膚觸廠築糧 (廠獵淵廠淵憲鏇糧鏇淵 )	-	2008-05-20
ASCO2007	临床1期	晚期恶性实体瘤	-	XL647	獵觸構繭蓋鹹餘網範積(鬱鹹憲鹹醖選構壓鑰醖) = 遞獵範醖淵網鏇糧夢遞繭選顧簾遞範膚憲製製 (壓網遞膚簾簾鹽蓋餘壓 ) 更多	-	2007-06-20
ASCO2005	临床1期	晚期恶性实体瘤	12	XL647	顧顧糧積艱鏇鏇餘網夢(獵簾繭齋觸齋觸鑰繭鑰) = 網夢築蓋醖鹹選製衊鑰繭獵構衊淵獵壓網網繭 (蓋獵製製淵膚憲鬱鹽齋 ) 更多	-	2005-06-01